Celiac Disease Diagnostics Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The Celiac Disease Diagnostics Market is projected to grow from USD 307.3 million in 2024 to USD 568.79 million by 2032, at a robust compound annual growth rate (CAGR) of 8% during the forecast period.
The market is driven by the rising global prevalence of celiac disease, coupled with increasing awareness of the condition and its complications. Significant advancements in diagnostic technologies, such as serological tests and genetic screening, have enabled earlier detection and improved disease management. The adoption of non-invasive diagnostic methods and the growing focus on personalized medicine further boost market growth. Additionally, supportive government initiatives aimed at promoting early diagnosis and treatment of autoimmune disorders have increased demand for diagnostic solutions. The development of advanced point-of-care testing devices, offering faster and more convenient detection, is a key trend. The integration of artificial intelligence (AI) and machine learning (ML) into diagnostic tools has also enhanced their accuracy and predictive capabilities, further contributing to the market’s growth.
Market Drivers
Advancements in Diagnostic Technologies
Technological innovations have significantly improved the accuracy and efficiency of celiac disease detection. For example, Quest Diagnostics has introduced next-generation serological tests that reduce diagnostic time and improve patient outcomes. These innovations, including next-generation serological tests, genetic screening, and point-of-care testing devices, enable healthcare professionals to diagnose celiac disease more effectively and quickly, driving market growth.
Market Challenges Analysis
Limited Awareness and Underdiagnosis
Despite increased awareness, a major challenge facing the Celiac Disease Diagnostics Market is the continued underdiagnosis of the condition. Many individuals remain undiagnosed due to a lack of awareness about the disease’s symptoms and potential severity. This issue is particularly pronounced in emerging economies where awareness campaigns and educational initiatives may be insufficient. Misdiagnosis is also common due to the overlap in symptoms with other gastrointestinal disorders, leading to delayed intervention and increasing the risk of long-term complications. These factors limit the growth potential of the market, highlighting the need for broader educational initiatives, improved healthcare provider training, and better diagnostic protocols to address these critical gaps.
Segmentation
By Treatment
Vitamins & Minerals
Gluten-Free Diet
Medical Therapies
Infliximab
Larazotide Acetate
Azathioprine
Budesonide
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospitals
Research Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-East Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Amneal Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Zydus Pharmaceuticals, Inc.
Amgen Inc.
Hikma Pharmaceuticals PLC
BioLineRx Ltd.
Glenmark Life Sciences Limited
Viatris Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
The Celiac Disease Diagnostics Market is projected to grow from USD 307.3 million in 2024 to USD 568.79 million by 2032, at a robust compound annual growth rate (CAGR) of 8% during the forecast period.
The market is driven by the rising global prevalence of celiac disease, coupled with increasing awareness of the condition and its complications. Significant advancements in diagnostic technologies, such as serological tests and genetic screening, have enabled earlier detection and improved disease management. The adoption of non-invasive diagnostic methods and the growing focus on personalized medicine further boost market growth. Additionally, supportive government initiatives aimed at promoting early diagnosis and treatment of autoimmune disorders have increased demand for diagnostic solutions. The development of advanced point-of-care testing devices, offering faster and more convenient detection, is a key trend. The integration of artificial intelligence (AI) and machine learning (ML) into diagnostic tools has also enhanced their accuracy and predictive capabilities, further contributing to the market’s growth.
Market Drivers
Advancements in Diagnostic Technologies
Technological innovations have significantly improved the accuracy and efficiency of celiac disease detection. For example, Quest Diagnostics has introduced next-generation serological tests that reduce diagnostic time and improve patient outcomes. These innovations, including next-generation serological tests, genetic screening, and point-of-care testing devices, enable healthcare professionals to diagnose celiac disease more effectively and quickly, driving market growth.
Market Challenges Analysis
Limited Awareness and Underdiagnosis
Despite increased awareness, a major challenge facing the Celiac Disease Diagnostics Market is the continued underdiagnosis of the condition. Many individuals remain undiagnosed due to a lack of awareness about the disease’s symptoms and potential severity. This issue is particularly pronounced in emerging economies where awareness campaigns and educational initiatives may be insufficient. Misdiagnosis is also common due to the overlap in symptoms with other gastrointestinal disorders, leading to delayed intervention and increasing the risk of long-term complications. These factors limit the growth potential of the market, highlighting the need for broader educational initiatives, improved healthcare provider training, and better diagnostic protocols to address these critical gaps.
Segmentation
By Treatment
Vitamins & Minerals
Gluten-Free Diet
Medical Therapies
Infliximab
Larazotide Acetate
Azathioprine
Budesonide
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospitals
Research Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-East Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Amneal Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Zydus Pharmaceuticals, Inc.
Amgen Inc.
Hikma Pharmaceuticals PLC
BioLineRx Ltd.
Glenmark Life Sciences Limited
Viatris Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Table of Contents
200 Pages
- CHAPTER NO. 1: INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2: EXECUTIVE SUMMARY
- 2.1. [Celiac Disease Diagnostics Market] Snapshot
- [Celiac Disease Diagnostics Market], 2018 - 2032 (USD Million)
- CHAPTER NO. 3: [Celiac Disease Diagnostics Market] – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4: ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. [Celiac Disease Diagnostics Market] Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups /SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5: PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6: [Celiac Disease Diagnostics Market] – BY [Based on Treatment] ANALYSIS
- CHAPTER NO. 7: [Celiac Disease Diagnostics Market] – BY [Based on Route of Administration] ANALYSIS
- CHAPTER NO. 8: [Celiac Disease Diagnostics Market] – BY [Based on Distribution Channel] ANALYSIS
- CHAPTER NO. 9: [Celiac Disease Diagnostics Market] – BY [Based on the Geography] ANALYSIS
- CHAPTER NO. 10: COMPANY PROFILES
- 9.1. Amneal Pharmaceuticals LLC
- 9.1.1. Company Overview
- 9.1.2. Product Portfolio
- 9.1.3. SWOT Analysis
- 9.1.4. Business Strategy
- 9.1.5. Financial Overview
- 9.2. Takeda Pharmaceutical Company Limited
- 9.3. Zydus Pharmaceuticals, Inc.
- 9.4. Amgen Inc.
- 9.5. Hikma Pharmaceuticals PLC
- 9.6. BioLineRx Ltd.
- 9.7. Glenmark Life Sciences Limited
- 9.8. Viatris Inc.
- 9.9. Novartis AG
- 9.10. Teva Pharmaceutical Industries Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
